The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nebivolol. Trifluoperazine may increase the hypotensive activities of Nebivolol. Nebivolol may increase the hypoglycemic activities of Glimepiride. Dihydroergotamine may increase the atrioventricular blocking (AV block) activities of Nebivolol. Nebivolol may increase the bradycardic activities of Crizotinib. The serum concentration of Nebivolol can be increased when it is combined with Nicardipine. Nebivolol may increase the bradycardic activities of Digitoxin. Nebivolol may decrease the bronchodilatory activities of Pirbuterol. Tinoridine may decrease the antihypertensive activities of Nebivolol. Pentoxifylline may increase the hypotensive activities of Nebivolol. The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nebivolol. The risk or severity of adverse effects can be increased when Carteolol is combined with Nebivolol. Bromfenac may decrease the antihypertensive activities of Nebivolol. Gallamine Triethiodide may increase the bradycardic activities of Nebivolol. Nebivolol may decrease the bronchodilatory activities of Phenylpropanolamine. The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nebivolol. The serum concentration of Nebivolol can be increased when it is combined with Fluvoxamine. Seratrodast may decrease the antihypertensive activities of Nebivolol. The risk or severity of adverse effects can be increased when Nadolol is combined with Nebivolol. Toloxatone may increase the hypotensive activities of Nebivolol. Nebivolol may increase the hypotensive activities of Indenolol. The risk or severity of adverse effects can be increased when Diltiazem is combined with Nebivolol. The risk or severity of adverse effects can be increased when Isradipine is combined with Nebivolol. Acetylsalicylic acid may decrease the antihypertensive activities of Nebivolol. Apomorphine may increase the atrioventricular blocking (AV block) activities of Nebivolol. Nebivolol may decrease the bronchodilatory activities of Formoterol. Bosentan may increase the hypotensive activities of Nebivolol. Mesoridazine may increase the hypotensive activities of Nebivolol. Methamphetamine may increase the atrioventricular blocking (AV block) activities of Nebivolol. Metamizole may decrease the antihypertensive activities of Nebivolol. The risk or severity of adverse effects can be increased when Metipranolol is combined with Nebivolol. Nebivolol may increase the hypotensive activities of Lacidipine. Promethazine may increase the hypotensive activities of Nebivolol. The risk or severity of adverse effects can be increased when Nitroprusside is combined with Nebivolol. The risk or severity of adverse effects can be increased when Furosemide is combined with Nebivolol. Nebivolol may increase the hypoglycemic activities of Glipizide. Nebivolol may increase the hypoglycemic activities of Gliquidone. The risk or severity of adverse effects can be increased when Acebutolol is combined with Nebivolol. Oxyphenbutazone may decrease the antihypertensive activities of Nebivolol. Selegiline may increase the hypotensive activities of Nebivolol. Nebivolol may increase the hypotensive activities of Theodrenaline. Icatibant may decrease the antihypertensive activities of Nebivolol. Nebivolol may increase the hypotensive activities of Hexamethonium. Piroxicam may decrease the antihypertensive activities of Nebivolol. The risk or severity of adverse effects can be increased when Pipamperone is combined with Nebivolol. Phenobarbital may increase the hypotensive activities of Nebivolol. The serum concentration of Nebivolol can be increased when it is combined with Diphenhydramine. Nebivolol may increase the hypoglycemic activities of Tolazamide. The risk or severity of adverse effects can be increased when Nebivolol is combined with Epibatidine. The serum concentration of Nebivolol can be increased when it is combined with Duloxetine. Indoprofen may decrease the antihypertensive activities of Nebivolol. The serum concentration of Nebivolol can be increased when it is combined with Eliglustat. Etoricoxib may decrease the antihypertensive activities of Nebivolol. Platelet Activating Factor may increase the hypotensive activities of Nebivolol. The risk or severity of adverse effects can be increased when Torasemide is combined with Nebivolol. The risk or severity of adverse effects can be increased when Nebivolol is combined with Lobeline. The risk or severity of adverse effects can be increased when Timolol is combined with Nebivolol. Zaltoprofen may decrease the antihypertensive activities of Nebivolol. Mycophenolate mofetil may decrease the antihypertensive activities of Nebivolol. Teriflunomide may decrease the antihypertensive activities of Nebivolol. The risk or severity of adverse effects can be increased when Arotinolol is combined with Nebivolol. Pirlindole may increase the hypotensive activities of Nebivolol. Brimonidine may increase the antihypertensive activities of Nebivolol. The risk or severity of adverse effects can be increased when Amlodipine is combined with Nebivolol. Nebivolol may increase the hypoglycemic activities of Tolbutamide. Malathion may increase the bradycardic activities of Nebivolol. Nebivolol may increase the bradycardic activities of Poractant alfa. Nebivolol may decrease the bronchodilatory activities of Salmeterol. The serum concentration of Nebivolol can be increased when it is combined with Stiripentol. The risk or severity of adverse effects can be increased when Nebivolol is combined with Arecoline. Parecoxib may decrease the antihypertensive activities of Nebivolol. Nebivolol may increase the orthostatic hypotensive activities of Indoramin. The risk or severity of adverse effects can be increased when Metolazone is combined with Nebivolol. Serrapeptase may decrease the antihypertensive activities of Nebivolol. Semapimod may decrease the antihypertensive activities of Nebivolol. Nebivolol may increase the hypoglycemic activities of Glisoxepide. Nebivolol may decrease the bronchodilatory activities of Salbutamol. The serum concentration of Nebivolol can be increased when it is combined with Cocaine. Meclofenamic acid may decrease the antihypertensive activities of Nebivolol. Mirodenafil may increase the antihypertensive activities of Nebivolol. The risk or severity of adverse effects can be increased when Triamterene is combined with Nebivolol. Distigmine may increase the bradycardic activities of Nebivolol. The metabolism of Nebivolol can be decreased when combined with Hydroxychloroquine. Nebivolol may decrease the bronchodilatory activities of Olodaterol. Salicylic acid may decrease the antihypertensive activities of Nebivolol. The serum concentration of Nebivolol can be increased when it is combined with Atomoxetine. Nebivolol may decrease the bronchodilatory activities of Ritodrine. The risk or severity of adverse effects can be increased when Lisinopril is combined with Nebivolol. Nebivolol may increase the orthostatic hypotensive activities of Doxazosin. Nebivolol may increase the hypotensive activities of Sitaxentan. Methylphenobarbital may increase the hypotensive activities of Nebivolol. The metabolism of Nebivolol can be decreased when combined with Amodiaquine. Nebivolol may increase the hypoglycemic activities of Chlorpropamide. Pergolide may increase the atrioventricular blocking (AV block) activities of Nebivolol. Hydracarbazine may increase the hypotensive activities of Nebivolol. Rofecoxib may decrease the antihypertensive activities of Nebivolol. Nebivolol may increase the bradycardic activities of Fingolimod. Methanesulfonyl Fluoride may increase the bradycardic activities of Nebivolol. Iloprost may increase the hypotensive activities of Nebivolol. Spirapril may increase the hypotensive activities of Nebivolol. The risk or severity of adverse effects can be increased when Ramipril is combined with Nebivolol. Epinephrine may increase the atrioventricular blocking (AV block) activities of Nebivolol. Minaprine may increase the hypotensive activities of Nebivolol. The risk or severity of adverse effects can be increased when Methazolamide is combined with Nebivolol. Bufexamac may decrease the antihypertensive activities of Nebivolol. The risk or severity of adverse effects can be increased when Nebivolol is combined with Canagliflozin. Flurbiprofen may decrease the antihypertensive activities of Nebivolol. Thiethylperazine may increase the hypotensive activities of Nebivolol. Phenelzine may increase the hypotensive activities of Nebivolol. Disopyramide may increase the bradycardic activities of Nebivolol. The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nebivolol. The risk or severity of adverse effects can be increased when Rotigotine is combined with Nebivolol. Methohexital may increase the hypotensive activities of Nebivolol. Tadalafil may increase the antihypertensive activities of Nebivolol. Tizanidine may increase the atrioventricular blocking (AV block) activities of Nebivolol. The serum concentration of Nebivolol can be increased when it is combined with Midostaurin. Nebivolol may increase the bradycardic activities of Deslanoside. The risk or severity of adverse effects can be increased when Imidapril is combined with Nebivolol. Remikiren may increase the hypotensive activities of Nebivolol. The risk or severity of adverse effects can be increased when Diclofenamide is combined with Nebivolol. The serum concentration of Nebivolol can be increased when it is combined with Delavirdine. Moxonidine may increase the atrioventricular blocking (AV block) activities of Nebivolol. Evening primrose oil may decrease the antihypertensive activities of Nebivolol. Galantamine may increase the bradycardic activities of Nebivolol. Omapatrilat may increase the hypotensive activities of Nebivolol. The serum concentration of Nebivolol can be increased when it is combined with Dosulepin. The risk or severity of adverse effects can be increased when Olmesartan is combined with Nebivolol. Nebivolol may increase the hypotensive activities of Risperidone. Nebivolol may increase the orthostatic hypotensive activities of Carvedilol. Nebivolol may increase the hypotensive activities of Talinolol.